Latest Medical Devices News

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

TruScreen Group Limited has announced a NZ$3 million capital raise to fund strategic growth initiatives across Asia and Africa, alongside repaying existing debt. The raise includes a placement and share purchase plan with free attaching options, signaling confidence in its expanding cervical cancer screening programs.

Aroa Biosurgery has reported FY25 results that exceed revenue guidance and deliver a positive normalised EBITDA, setting the stage for ambitious growth and reimbursement expansion in FY26.

Fisher & Paykel Healthcare has announced an ordinary dividend of NZD 0.28235294 per share for the six months ending March 31, 2025, payable on July 4. The dividend is unfranked and includes a supplementary component, with a 15% withholding tax applied.

ReNerve Limited has gained marketing approval for its NervAlign® Nerve Cuff™ in Bahrain, marking its first regulatory success in the Middle East and opening access to a rapidly expanding regional market.

Fisher & Paykel Healthcare has reported a record full-year revenue of NZ$2.02 billion for FY2025, alongside a 43% increase in underlying net profit after tax. The company also raised its dividend, reflecting strong operational performance and strategic investments.

Atomo Diagnostics has landed a significant $450,000 order to supply HIV self-tests for a federally funded Australian program aimed at increasing at-home testing among high-risk groups.

OncoSil Medical has secured $8.7 million through a placement and share purchase plan to fund commercialization of its pancreatic cancer treatment device, aiming for positive cash flow by mid-2026. Near-completion clinical trials could soon unlock broader market access.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.

TruScreen Group Limited reported a 19% revenue decline in FY2025 due to delayed rollouts in key emerging markets but anticipates a strong rebound with FY2026 sales forecast to exceed NZ$2.8 million.

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.